Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0814 CureVac IPO
BioCentury & Getty Images

Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

German COVID-19 vaccine maker finishes trading debut valued at nearly $10B after $213M IPO

Backed for years by Dietmar Hopp alone, German mRNA company finishes first trading day valued at nearly $10 billion after raising $213 million in a NASDAQ IPO.

Aug 15, 2020 | 1:14 AM GMT

CureVac’s

Read the full 614 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE